Pharmacokinetic Pharmacogenetic Prescribing Guidelines for Antidepressants: A Template for Psychiatric Precision Medicine

Mayo Clinic Proceedings

Volumn 91, Issue 7, 2016, Pages 897-907

  Nassan, Malik ^a   Nicholson, Wayne T ^a   Elliott, Michelle A ^a   Rohrer Vitek, Carolyn R ^a   Black, John L ^a   Frye, Mark A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; CLONIDINE; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; DESVENLAFAXINE; ESCITALOPRAM; FLUOXETINE; METHYLPHENIDATE; NORFLUOXETINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE; CYTOCHROME P450 INHIBITOR; PRESCRIPTION DRUG;

ALLELE; AREA UNDER THE CURVE; BINDING AFFINITY; BLOOD TOXICITY; CARDIOTOXICITY; CONCENTRATION RESPONSE; DEPRESSION; DIARRHEA; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ENZYME ACTIVITY; GASTROINTESTINAL DISEASE; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; GILLES DE LA TOURETTE SYNDROME; HEART ARREST; HUMAN; HYPONATREMIA; MAJOR DEPRESSION; NAUSEA; OBSESSIVE COMPULSIVE DISORDER; PERSONALIZED MEDICINE; PHARMACOGENETICS; PRACTICE GUIDELINE; PSYCHOPHARMACOTHERAPY; QT PROLONGATION; REVIEW; SEROTONIN SYNDROME; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING; VOMITING; DEPRESSIVE DISORDER, MAJOR; GENETICS; PROCEDURES; STANDARDS;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME INHIBITORS; DEPRESSIVE DISORDER, MAJOR; FLUOXETINE; HUMANS; PAROXETINE; PHARMACOGENETICS; PRACTICE GUIDELINES AS TOPIC; PRECISION MEDICINE; PRESCRIPTION DRUGS; VENLAFAXINE HYDROCHLORIDE;

EID: 84991666760     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2016.02.023     Document Type: Review

References (113)

1. 1 Collins, F.S., Varmus, H., A new initiative on precision medicine. N Engl J Med 372:9 (2015), 793–795.
2. 2 Green, E.D., Guyer, M.S., National Human Genome Research Institute. Charting a course for genomic medicine from base pairs to bedside. Nature 470:7333 (2011), 204–213.
3. 3 Zhong, W., Maradit-Kremers, H., St Sauver, J.L., et al. Age and sex patterns of drug prescribing in a defined American population. Mayo Clin Proc 88:7 (2013), 697–707.
4. 4 Schatzberg, A.F., Nemeroff, C.B., (eds.) The American Psychiatric Publishing Textbook of Psychopharmacology, 4th ed., 2009, American Psychiatric Publishing, Washington, DC.
5. 5 Bloch, M.H., McGuire, J., Landeros-Weisenberger, A., Leckman, J.F., Pittenger, C., Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder. Mol Psychiatry 15:8 (2010), 850–855.
6. 6 Fabbri, C., Porcelli, S., Serretti, A., From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment. Can J Psychiatry 59:2 (2014), 62–75.
7. 7 Biernacka, J.M., Sangkuhl, K., Jenkins, G., et al. The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response. Transl Psychiatry, 5, 2015, e553.
8. 8 Ellsworth, K.A., Moon, I., Eckloff, B.W., et al. FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder. Pharmacogenet Genomics 23:3 (2013), 156–166.
9. 9 Ji, Y., Biernacka, J.M., Hebbring, S., et al. Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics. Pharmacogenomics J 13:5 (2013), 456–463.
10. 10 Rush, A.J., Trivedi, M.H., Wisniewski, S.R., et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 163:11 (2006), 1905–1917.
11. 11 Ferrell, P.B. Jr., McLeod, H.L., Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics 9:10 (2008), 1543–1546.
12. 12 Amstutz, U., Shear, N.H., Rieder, M.J., et al., CPNDS Clinical Recommendation Group. Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions. Epilepsia 55:4 (2014), 496–506.
13. 13 Binkhorst, L., Mathijssen, R.H., van Herk-Sukel, M.P., et al. Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen. Breast Cancer Res Treat 139:3 (2013), 923–929.
14. 14 Bielinski, S.J., Olson, J.E., Pathak, J., et al. Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time—using genomic data to individualize treatment protocol. Mayo Clin Proc 89:1 (2014), 25–33.
15. 15 Ingelman-Sundberg M, Daly AK, Nebert DW. Allele nomenclature for Cytochrome P450 enzymes. http://www.cypalleles.ki.se/index.htm. Accessed March 29, 2016.
16. 16 Sim, S.C., Ingelman-Sundberg, M., The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects. Hum Genomics 4:4 (2010), 278–281.
17. 17 Whirl-Carrillo, M., McDonagh, E.M., Hebert, J.M., et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 92:4 (2012), 414–417.
18. 18 Black, J.L. III, Walker, D.L., O'Kane, D.J., Harmandayan, M., Frequency of undetected CYP2D6 hybrid genes in clinical samples: impact on phenotype prediction. Drug Metab Dispos 40:1 (2012), 111–119.
19. 19 Skierka, J.M., Black, J.L. III, Analysis of compound heterozygous CYP2C19 genotypes to determine cis and trans configurations. Pharmacogenomics 15:9 (2014), 1197–1205.
20. 20 Gaedigk, A., Complexities of CYP2D6 gene analysis and interpretation. Int Rev Psychiatry 25:5 (2013), 534–553.
21. 21 Hicks, J.K., Bishop, J.R., Sangkuhl, K., et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther 98:2 (2015), 127–134.
22. 22 Crews, K.R., Gaedigk, A., Dunnenberger, H.M., et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther 95:4 (2014), 376–382.
23. 23 Spina, E., Santoro, V., D'Arrigo, C., Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther 30:7 (2008), 1206–1227.
24. 24 Preskorn, S.H., Kane, C.P., Lobello, K., et al. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine. J Clin Psychiatry 74:6 (2013), 614–621.
25. 25 Gardiner, S.J., Begg, E.J., Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev 58:3 (2006), 521–590.
26. 26 Preskorn, S.H., Reproducibility of the in vivo effect of the selective serotonin reuptake inhibitors on the in vivo function of cytochrome P450 2D6: an update (part I). J Psychiatr Pract 9:2 (2003), 150–158.
27. 27 Preskorn, S.H., Reproducibility of the in vivo effect of the selective serotonin reuptake inhibitors on the in vivo function of cytochrome P450 2D6: an update (part II). J Psychiatr Pract 9:3 (2003), 228–236.
28. 28 Kaye, C.M., Haddock, R.E., Langley, P.F., et al. A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand Suppl 350 (1989), 60–75.
29. 29 Tang, S.W., Helmeste, D., Paroxetine. Expert Opin Pharmacother 9:5 (2008), 787–794.
30. 30 Margolis, J.M., O'Donnell, J.P., Mankowski, D.C., Ekins, S., Obach, R.S., (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab Dispos 28:10 (2000), 1187–1191.
31. 31 Bloomer, J.C., Woods, F.R., Haddock, R.E., Lennard, M.S., Tucker, G.T., The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes. Br J Clin Pharmacol 33:5 (1992), 521–523.
32. 32 Sindrup, S.H., Brøsen, K., Gram, L.F., Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Clin Pharmacol Ther 51:3 (1992), 288–295.
33. 33 US Food and Drug Administration. Prozac (fluoxetine hydrochloride) delayed release capsules: detailed view: safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER). US Food and Drug Administration website. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm364458.htm. Published July 2013. Updated August 12, 2013. Accessed December 1, 2015.
34. 34 Jakubovski, E., Varigonda, A.L., Freemantle, N., Taylor, M.J., Bloch, M.H., Systematic review and meta-analysis: dose-response relationship of selective serotonin reuptake inhibitors in major depressive disorder. Am J Psychiatry 173:2 (2016), 174–183.
35. 35 Anderson, I.M., Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 58:1 (2000), 19–36.
36. 36 Bull, S.A., Hunkeler, E.M., Lee, J.Y., et al. Discontinuing or switching selective serotonin-reuptake inhibitors. Ann Pharmacother 36:4 (2002), 578–584.
37. 37 Linden, M., Gothe, H., Dittmann, R.W., Schaaf, B., Early termination of antidepressant drug treatment. J Clin Psychopharmacol 20:5 (2000), 523–530.
38. 38 Hu, X.H., Bull, S.A., Hunkeler, E.M., et al. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry 65:7 (2004), 959–965.
39. 39 Masand, P.S., Tolerability and adherence issues in antidepressant therapy. Clin Ther 25:8 (2003), 2289–2304.
40. 40 Morehouse, R., Macqueen, G., Kennedy, S.H., Barriers to achieving treatment goals: a focus on sleep disturbance and sexual dysfunction. J Affect Disord 132:suppl 1 (2011), S14–S20.
41. 41 Charlier, C., Broly, F., Lhermitte, M., Pinto, E., Ansseau, M., Plomteux, G., Polymorphisms in the CYP 2D6 gene: association with plasma concentrations of fluoxetine and paroxetine. Ther Drug Monit 25:6 (2003), 738–742.
42. 42 Alderman, J., Preskorn, S.H., Greenblatt, D.J., et al. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol 17:4 (1997), 284–291.
43. 43 Nichols, A.I., Fatato, P., Shenouda, M., et al. The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults. J Clin Pharmacol 49:2 (2009), 219–228.
44. 44 Sato, A., Okura, Y., Minagawa, S., et al. Life-threatening serotonin syndrome in a patient with chronic heart failure and CYP2D6*1/*5. Mayo Clin Proc 79:11 (2004), 1444–1448.
45. 45 Alexandrino-Silva, C., Nadalini Mauá, F.H., de Andrade, A.G., de Toledo Ferraz Alves, T.C., Hypotension caused by therapeutic doses of venlafaxine: case report and proposed pathophysiological mechanisms. J Psychopharmacol 22:2 (2008), 214–216.
46. 46 Vinetti, M., Haufroid, V., Capron, A., Classen, J.F., Marchandise, S., Hantson, P., Severe acute cardiomyopathy associated with venlafaxine overdose and possible role of CYP2D6 and CYP2C19 polymorphisms. Clin Toxicol (Phila) 49:9 (2011), 865–869.
47. 47 Chua, E.W., Foulds, J., Miller, A.L., Kennedy, M.A., Novel CYP2D6 and CYP2C19 variants identified in a patient with adverse reactions towards venlafaxine monotherapy and dual therapy with nortriptyline and fluoxetine. Pharmacogenet Genomics 23:9 (2013), 494–497.
48. 48 Shams, M.E., Arneth, B., Hiemke, C., et al. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther 31:5 (2006), 493–502.
49. 49 Stedman, C.A., Begg, E.J., Kennedy, M.A., Roberts, R., Wilkinson, T.J., Cytochrome P450 2D6 genotype does not predict SSRI (fluoxetine or paroxetine) induced hyponatraemia. Hum Psychopharmacol 17:4 (2002), 187–190.
50. 50 Kumar, Y., Kung, S., Shinozaki, G., CYP2C19 variation, not citalopram dose nor serum level, is associated with QTc prolongation. J Psychopharmacol 28:12 (2014), 1143–1148.
51. 51 Cooke, M.J., Waring, W.S., Citalopram and cardiac toxicity. Eur J Clin Pharmacol 69:4 (2013), 755–760.
52. 52 Jornil, J., Nielsen, T.S., Rosendal, I., et al. A poor metabolizer of both CYP2C19 and CYP2D6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine. Forensic Sci Int 226:1-3 (2013), e26–e31.
53. 53 Sallee, F.R., DeVane, C.L., Ferrell, R.E., Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency. J Child Adolesc Psychopharmacol 10:1 (2000), 27–34.
54. 54 Wu, A.H., Kearney, T., Lack of impairment due to confirmed codeine use prior to a motor vehicle accident: role of pharmacogenomics. J Forensic Leg Med 20:8 (2013), 1024–1027.
55. 55 Karki, S.D., Masood, G.R., Combination risperidone and SSRI-induced serotonin syndrome. Ann Pharmacother 37:3 (2003), 388–391.
56. 56 Preskorn, S.H., Clinical psychopharmacology and medical malpractice: the four Ds. J Psychiatr Pract 20:5 (2014), 363–368.
57. 57 Gassó, P., Mas, S., Papagianni, K., et al. Effect of CYP2D6 on risperidone pharmacokinetics and extrapyramidal symptoms in healthy volunteers: results from a pharmacogenetic clinical trial. Pharmacogenomics 15:1 (2014), 17–28.
58. 58 Brandl, E.J., Tiwari, A.K., Chowdhury, N.I., et al. Genetic variation in the GCG and in the GLP1R genes and antipsychotic-induced weight gain. Pharmacogenomics 15:4 (2014), 423–431.
59. 59 Gasso, P., Rodriguez, N., Mas, S., et al. Effect of CYP2D6, CYP2C9 and ABCB1 genotypes on fluoxetine plasma concentrations and clinical improvement in children and adolescent patients. Pharmacogenomics J 14:5 (2014), 457–462.
60. 60 Fjordside, L., Jeppesen, U., Eap, C.B., Powell, K., Baumann, P., Brøsen, K., The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine. Pharmacogenetics 9:1 (1999), 55–60.
61. 61 Brandl, E.J., Tiwari, A.K., Zhou, X., et al. Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder. Pharmacogenomics J 14:2 (2014), 176–181.
62. 62 Gex-Fabry, M., Eap, C.B., Oneda, B., et al. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. Ther Drug Monit 30:4 (2008), 474–482.
63. 63 Güzey, C., Spigset, O., Low serum concentrations of paroxetine in CYP2D6 ultrarapid metabolizers. J Clin Psychopharmacol 26:2 (2006), 211–212.
64. 64 Lam, Y.W., Gaedigk, A., Ereshefsky, L., Alfaro, C.L., Simpson, J., CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6. Pharmacotherapy 22:8 (2002), 1001–1006.
65. 65 Gressier, F., Verstuyft, C., Hardy, P., Becquemont, L., Corruble, E., Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors. J Neural Transm (Vienna) 122:1 (2015), 35–42.
66. 66 Lobello, K.W., Preskorn, S.H., Guico-Pabia, C.J., et al. Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder. J Clin Psychiatry 71:11 (2010), 1482–1487.
67. 67 Altar, C.A., Carhart, J.M., Allen, J.D., Hall-Flavin, D.K., Dechairo, B.M., Winner, J.G., Clinical validity: combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes. Pharmacogenomics J 15:5 (2015), 443–451.
68. 68 Hall-Flavin, D.K., Winner, J.G., Allen, J.D., et al. Using a pharmacogenomic algorithm to guide the treatment of depression. Transl Psychiatry, 2, 2012, e172.
69. 69 Hall-Flavin, D.K., Winner, J.G., Allen, J.D., et al. Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenet Genomics 23:10 (2013), 535–548.
70. 70 Perlis, R.H., Pharmacogenomic testing and personalized treatment of depression. Clin Chem 60:1 (2014), 53–59.
71. 71 Berm, E.J., Hak, E., Postma, M., et al. Effects and cost-effectiveness of pharmacogenetic screening for CYP2D6 among older adults starting therapy with nortriptyline or venlafaxine: study protocol for a pragmatic randomized controlled trial (CYSCEtrial). Trials, 16, 2015, 37.
72. 72 Squassina, A., Manchia, M., Manolopoulos, V.G., et al. Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice. Pharmacogenomics 11:8 (2010), 1149–1167.
73. 73 Carlberg, C., The need for education in personalized medicine. Personalized Med 9:2 (2012), 147–150.
74. 74 Callier, S.L., Toma, I., McCaffrey, T., Harralson, A.F., O'Brien, T.J., Engaging the next generation of healthcare professionals in genomics: planning for the future. Personalized Med 11:1 (2014), 89–98.
75. 75 Formea, C.M., Nicholson, W.T., Rohrer Vitek, C., An inter-professional approach to personalized medicine education: one institution's experience. Personalized Med 12:2 (2015), 129–138.
76. 76 Cook, D.A., Sorensen, K.J., Nishimura, R.A., Ommen, S.R., Lloyd, F.J., A comprehensive information technology system to support physician learning at the point of care. Acad Med 90:1 (2015), 33–39.
77. 77 US Food and Drug Administration. Drug development and drug interactions: table of substrates, inhibitors and inducers. US Food and Drug Administration website. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm. Updated October 27, 2014. Accessed December 1, 2015.
78. 78 Purgato, M., Papola, D., Gastaldon, C., et al. Paroxetine versus other anti-depressive agents for depression. Cochrane Database Syst Rev, 4, 2014, CD006531.
79. 79 Magni, L.R., Purgato, M., Gastaldon, C., et al. Fluoxetine versus other types of pharmacotherapy for depression. Cochrane Database Syst Rev, 7, 2013, CD004185.
80. 80 Cipriani, A., Santilli, C., Furukawa, T.A., et al. Escitalopram versus other antidepressive agents for depression. Cochrane Database Syst Rev(2), 2009, CD006532.
81. 81 Baumann, P., Hiemke, C., Ulrich, S., et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 37:6 (2004), 243–265.
82. 82 Adli, M., Baethge, C., Heinz, A., Langlitz, N., Bauer, M., Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? a systematic review. Eur Arch Psychiatry Clin Neurosci 255:6 (2005), 387–400.
83. 83 Grandjean, E.M., Aubry, J.M., Lithium: updated human knowledge using an evidence-based approach, part II: Clinical pharmacology and therapeutic monitoring. CNS Drugs 23:4 (2009), 331–349.
84. 84 Fleming, J., Chetty, M., Therapeutic monitoring of valproate in psychiatry: how far have we progressed?. Clin Neuropharmacol 29:6 (2006), 350–360.
85. 85 Bollini, P., Pampallona, S., Tibaldi, G., Kupelnick, B., Munizza, C., Effectiveness of antidepressants: meta-analysis of dose-effect relationships in randomised clinical trials. Br J Psychiatry 174 (1999), 297–303.
86. 86 Wille, S.M., Cooreman, S.G., Neels, H.M., Lambert, W.E., Relevant issues in the monitoring and the toxicology of antidepressants. Crit Rev Clin Lab Sci 45:1 (2008), 25–89.
87. 87 Thanacoody, H.K., Thomas, S.H., Antidepressant poisoning. Clin Med (Lond) 3:2 (2003), 114–118.
88. 88 Baumann, P., Ulrich, S., Eckermann, G., et al. The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants. Dialogues Clin Neurosci 7:3 (2005), 231–247.
89. 89 Blázquez, A., Mas, S., Plana, M.T., et al. Plasma fluoxetine concentrations and clinical improvement in an adolescent sample diagnosed with major depressive disorder, obsessive-compulsive disorder, or generalized anxiety disorder. J Clin -Psychopharmacol 34:3 (2014), 318–326.
90. 90 Preskorn, S.H., Therapeutic drug monitoring (TDM) in psychiatry (part I): why studies attempting to correlate drug concentration and antidepressant response don't work. J Psychiatr Pract 20:2 (2014), 133–137.
91. 91 Bjerkenstedt, L., Flyckt, L., Overø, K.F., Lingjaerde, O., Relationship between clinical effects, serum drug concentration and serotonin uptake inhibition in depressed patients treated with citalopram: a double-blind comparison of three dose levels. Eur J Clin Pharmacol 28:5 (1985), 553–557.
92. 92 Dufour, H., Bouchacourt, M., Thermoz, P., et al. Citalopram—a highly selective 5-HT uptake inhibitor—in the treatment of depressed patients. Int Clin Psychopharmacol 2:3 (1987), 225–237.
93. 93 Preskorn, S.H., Fast, G.A., Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness. [published correction appears in J Clin Psychiatry. 1991;52(8):353] J Clin Psychiatry 52:suppl (1991), 23–33.
94. 94 Kelly, M.W., Perry, P.J., Holstad, S.G., Garvey, M.J., Serum fluoxetine and norfluoxetine concentrations and antidepressant response. Ther Drug Monit 11:2 (1989), 165–170.
95. 95 Bouquet, S., Vandel, S., Bertschy, G., et al. Pharmacokinetics of fluoxetine and fluvoxamine in depressed patients: personal results. Clin Neuropharmacol 15:suppl 1, pt A (1992), 82A–83A.
96. 96 Kasper, S., Dötsch, M., Kick, H., Vieira, A., Möller, H.J., Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects. Eur Neuropsychopharmacol 3:1 (1993), 13–21.
97. 97 Laursen, A.L., Mikkelsen, P.L., Rasmussen, S., le Fèvre Honoré, P., Paroxetine in the treatment of depression—a randomized comparison with amitriptyline. Acta Psychiatr Scand 71:3 (1985), 249–255.
98. 98 Preskorn, S.H., Clinically relevant pharmacology of selective serotonin reuptake inhibitors: an overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 32:suppl 1 (1997), 1–21.
99. 99 Preskorn, S.H., The use of biomarkers in psychiatric research: how serotonin transporter occupancy explains the dose-response curves of SSRIs. J Psychiatr Pract 18:1 (2012), 38–45.
100. 11C]DASB positron emission tomography study. Am J Psychiatry 161:5 (2004), 826–835.
101. 101 Spies, M., Knudsen, G.M., Lanzenberger, R., Kasper, S., The serotonin transporter in psychiatric disorders: insights from PET imaging. Lancet Psychiatry 2:8 (2015), 743–755.
102. 102 Schildcrout, J.S., Denny, J.C., Bowton, E., et al. Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping. Clin Pharmacol Ther 92:2 (2012), 235–242.
103. 103 National Center for Biotechnology Information. GTR: Genetic Testing Registry. National Center for Biotechnology Information website. http://www.ncbi.nlm.nih.gov/gtr/. Accessed December 1, 2015.
104. 104 Deverka, P.A., Pharmacogenomics, evidence, and the role of payers. Public Health Genomics 12:3 (2009), 149–157.
105. 105 Frueh, F.W., Real-world clinical effectiveness, regulatory transparency and payer coverage: three ingredients for translating pharmacogenomics into clinical practice. Pharmacogenomics 11:5 (2010), 657–660.
106. 106 Meckley, L.M., Neumann, P.J., Personalized medicine: factors influencing reimbursement. Health Policy 94:2 (2010), 91–100.
107. 107 Trosman, J.R., Van Bebber, S.L., Phillips, K.A., Coverage policy development for personalized medicine: private payer perspectives on developing policy for the 21-gene assay. J Oncol Pract 6:5 (2010), 238–242.
108. 108 Cohen, J., Wilson, A., Manzolillo, K., Clinical and economic challenges facing pharmacogenomics. Pharmacogenomics J 13:4 (2013), 378–388.
109. 109 Hresko, A., Haga, S.B., Insurance coverage policies for personalized medicine. J Pers Med 2:4 (2012), 201–216.
110. 110 Haghgoo, S.M., Allameh, A., Mortaz, E., et al. Pharmacogenomics and targeted therapy of cancer: focusing on non-small cell lung cancer. Eur J Pharmacol 754 (2015), 82–91.
111. 111 Esplin, E.D., Snyder, M.P., Genomic era diagnosis and management of hereditary and sporadic colon cancer. World J Clin Oncol 5:5 (2014), 1036–1047.
112. 112 Lopez-Lopez, E., Gutierrez-Camino, A., Bilbao-Aldaiturriaga, N., Pombar-Gomez, M., Martin-Guerrero, I., Garcia-Orad, A., Pharmacogenetics of childhood acute lymphoblastic leukemia. Pharmacogenomics 15:10 (2014), 1383–1398.
113. 113 Mrazek, D.A., Lerman, C., Facilitating clinical implementation of pharmacogenomics. JAMA 306:3 (2011), 304–305.